23andMe finds a buyer for its IL-36 bispecific in Almirall; Neurocrine, Idorsia revise epilepsy drug deal
→ The first fruits of 23andMe’s efforts to generate new drugs off the insights it gained from a massive amount of genetic data are taking shape, and Almirall is signing up to ripen one of them. The Spanish dermatology drugmaker has licensed a bispecific antibody that blocks three cytokines in the IL-36 cytokine family, which are tied to skin conditions such as psoriasis and lupus, in addition to other inflammatory ailments such as ulcerative colitis, inflammatory bowel disease, and Crohn’s disease.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters